Serplulimab
CAS No. 2231029-82-4
Serplulimab( —— )
Catalog No. M36682 CAS No. 2231029-82-4
Serplulimab (HLX 10) is a humanized monoclonal anti-antibody to PD-1. Serplulimab has antitumor activity and can be used in small cell lung cancer and esophageal squamous cell carcinoma.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 353 | In Stock |
|
| 10MG | 567 | In Stock |
|
| 25MG | 888 | In Stock |
|
| 50MG | 1172 | In Stock |
|
| 100MG | 1572 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameSerplulimab
-
NoteResearch use only, not for human use.
-
Brief DescriptionSerplulimab (HLX 10) is a humanized monoclonal anti-antibody to PD-1. Serplulimab has antitumor activity and can be used in small cell lung cancer and esophageal squamous cell carcinoma.
-
DescriptionSerplulimab (HLX 10) is humanized monoclonal anti-PD-1 antibody. Serplulimab can be used in research of small cell lung cancer.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayChromatin/Epigenetic
-
TargetCOX
-
RecptorCOX
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2231029-82-4
-
Formula Weight
-
Molecular Formula——
-
Purity>98% (HPLC)
-
Solubility——
-
SMILES——
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Lee A. Serplulimab: First Approval. Drugs. 2022 Jul;82(10):1137-1141.?
molnova catalog
related products
-
Amentoflavone
Amentoflavone can interact with many other medications by being a potent inhibitor of CYP3A4 and CYP2C9.
-
Orientin
Orientin may be regarded as a candidate therapeutic agent for treatment of vascular inflammatory diseases via inhibition of the HMGB1 signaling pathway.
-
Inulicin
Inulicin, an active compound isolated from Inula Britannica L, inhibits VEGF-mediated activation of Src and FAK.
Cart
sales@molnova.com